Biogen Idec Inc (BIIB): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biogen Idec ( BIIB) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.5%. By the end of trading, Biogen Idec fell $3.71 (-1.5%) to $236.59 on average volume. Throughout the day, 893,091 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,150,100 shares. The stock ranged in price between $235.59-$240.91 after having opened the day at $237.47 as compared to the previous trading day's close of $240.30. Other companies within the Health Care sector that declined today were: China Botanic Pharmaceutical ( CBP), down 98.2%, Atossa Genetics ( ATOS), down 46.4%, Mast Therapeutics ( MSTX), down 30.4% and Skystar Bio-Pharmaceutical Company ( SKBI), down 14.4%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $57.9 billion and is part of the drugs industry. Shares are up 66.4% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 254.8%, Cardiome Pharma Corporation ( CRME), up 24.9%, Cell Therapeutics ( CTIC), up 22.6% and Tekmira Pharmaceuticals Corporation ( TKMR), up 18.2%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire